Macrophage-derived soluble CD163 level in young patients with Gaucher disease: Relation to phenotypes, disease severity and complications

International Immunopharmacology

Volumn 24, Issue 2, 2015, Pages 416-422

  Adly, Amira Abdel Moneam ^a   Ismail, Eman Abdel Rahman ^a   Ibraheem, Taghreed Mahmoud ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bone mineral density; Gaucher disease; Pulmonary hypertension; sCD163; Severity score index

Indexed keywords

CD163 ANTIGEN; CHITOTRIOSIDASE; D DIMER; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; AGE; ARTICLE; BONE DENSITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEVELOPMENTAL DISORDER; DISEASE DURATION; DISEASE SEVERITY; DYSPHAGIA; ENZYME ACTIVITY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HUMAN; LEUKOCYTE COUNT; LIVER WEIGHT; LYMPHATIC PARAMETERS; MALE; OSTEOPENIA; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEVERITY SCORE INDEX; SPLEEN VOLUME; STRABISMUS; BLOOD; MACROPHAGE; METABOLISM; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS; CHILD; FEMALE; GAUCHER DISEASE; HEXOSAMINIDASES; HUMANS; MACROPHAGES; MALE; PHENOTYPE; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX;

EID: 84921033331     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.12.039     Document Type: Article

References (52)

1. E. Beutler, and G.A. Grabowski Gaucher disease C.R. Scriver, D. Valle, A. Beudet, W.S. Sly, The metabolic and molecular bases of inherited diseases vol. III 2001 McGraw-Hill New York 3635 3668
2. G.A. Grabowski Gaucher disease: lessons from a decade of therapy J Pediatr 144 2004 S15 S19
3. C. Mignot, D. Doummar, I. Maire, and T.B. de Villemeur Type 2 Gaucher disease: 15 new cases and review of the literature Brain Dev 28 2006 39 48
4. E. Sidransky Gaucher disease: complexity in a "simple" disorder Mol Genet Metab 83 2004 6 15
5. A. Mehta Epidemiology and natural history of Gaucher's disease Eur J Intern Med 17 2006 S2 S5
6. D.A. Hughes, A. Mlilligan, and A. Mehta Home therapy for lysosomal storage disorders Br J Nurs 16 1384 2007 1386 1389
7. O. Goitein, D. Elstein, A. Abrahamov, I. Hadas-Halpern, E. Melzer, and E. Kerem Lung involvement and enzyme replacement therapy in Gaucher's disease QJM 94 2001 407 415
8. M. Kozelj, S. Zver, and V. Zadnik Echocardiographic assessment of left ventricular function in type 1 Gaucher's disease Adv Hematol 2010 2010 [pii: 820843]
9. S. Sirrs, J. Irving, G. McCauley, K. Gin, B. Munt, and G. Pastores Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease J Inherit Metab Dis 25 2002 131 132
10. M. Jmoudiak, and A.H. Futerman Gaucher disease: pathological mechanisms and modern management Br J Haematol 129 2005 178 188
11. G.A. Grabowski, G. Andria, A. Baldellou, P.E. Campbell, J. Charrow, and I.J. Cohen Pediatric non-euronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements Eur J Ped 63 2004 58 66
12. L.E. Otterbein, M.P. Soares, K. Yamashita, and F.H. Bach Heme oxygenase-1: unleashing the protective properties of heme Trends Immunol 24 2003 449 455
13. M.R. Sarrias, J. Grønlund, O. Padilla, J. Madsen, U. Holmskov, and F. Lozano The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system Crit Rev Immunol 24 2004 1 37
14. N. Matsushita, M. Kashiwagi, R. Wait, R. Nagayoshi, M. Nakamura, and T. Matsuda Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3 Clin Exp Immunol 130 2002 156 161
15. H.J. Møller, M.J. Nielsen, M.B. Maniecki, M. Madsen, and S.K. Moestrup Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding Immunobiology 215 2010 406 412
16. M. Kolackova, M. Kudlova, P. Kunes, V. Lonsky, J. Mandak, and C. Andrys Early expression of FcgammaRI (CD64) on monocytes of cardiac surgical patients and higher density of monocyte anti-inflammatory scavenger CD163 receptor in "on-pump" patients Mediators Inflamm 2008 2008 235461
17. P. Allavena, A. Sica, G. Solinas, C. Porta, and A. Mantovani The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages Crit Rev Oncol Hematol 66 2008 1 9
18. C.E. Hollak, S. van Weely, M.H. van Oers, and J.M. Aerts Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease J Clin Invest 93 1994 1288 1292
19. M. de Fost, C.E. Hollak, J.E. Groener, J.M. Aerts, M Maas, and L.W. Poll Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 2006 830 835
20. T.M. Cox, and J.P. Schofield Gaucher's disease: clinical features and natural history Baillieres Clin Haematol 10 1997 657 689
21. R.G. Boot, C.E. Hollak, M. Verhoek, P. Sloof, B.J. Poorthuis, and W.J. Kleijer Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value Hum Mutat 10 1997 348 358
22. A. Zimran, A. Kay, T. Gelbart, P. Garver, D. Thurston, and A. Saven Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients Medicine (Baltimore) 71 1992 337 353
23. D. Elstein, I. Hadas-Halpren, Y. Azuri, A. Abrahamov, Y. Bar-Ziv, and A. Zimran Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements J Ultrasound Med 16 1997 209 211
24. F.D. Pashankar, J. Carbonella, A. Bazzy-Asaad, and A. Friedman Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease Pediatrics 121 2008 777 782
25. C.R. Morris, H.Y. Kim, F. Trachtenberg, J. Wood, C.T. Quinn, and N. Sweeters Thalassemia Clinical Research Network. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report Blood 118 2011 3794 3802
26. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group World Health Organ Tech Rep Ser 843 2004 1 129
27. N. Mattsson, S. Tabatabaei, P. Johansson, O. Hansson, U. Andreasson, and J.E. Mansson Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility Neuromolecular Med 13 2011 151 159
28. R.G. Boot, M.J. van Reemen, W. Wegdam, R.R. Sprenger, S. de Jong, and D. Speijer Gaucher disease: a model disorder for biomarker discovery Expert Rev Proteomics 6 2009 411 419
29. I. Maire, N. Guffon, and R. Froissart Current development and usefulness of biomarkers for Gaucher disease follow up Rev Med Interne 28 2007 S187 S192
30. A.S. Khalifa, A.A. Tantawy, R.M. Shawky, E. Monir, S.M. Elsayed, and E. Fateen Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience Egypt J Med Hum Genet 12 2011 9 14
31. I.J. Anderson, W. Henley, K.M. Wyatt, V. Nikolaou, S. Waldek, and D.A. Hughes Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study J Inherit Metab Dis 37 2014 961 968
32. G.A. Grabowski, G.A. Petsko, and E.H. Kolodny Gaucher disease D. Valle, A. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, The online metabolic and molecular bases of inherited diseases 2010 The McGraw-Hill Companies, Inc. New York
33. H.J. Møller Soluble CD163 Scand J Clin Lab Invest 72 1 2012 1 13
34. H.J. Møller, H. Aerts, H. Grønbaek, N.A. Peterslund, P. Hyltoft Petersen, and N. Hornung Soluble CD163: a marker molecule for monocyte/macrophage activity in disease Scand J Clin Lab Invest Suppl 237 2002 29 33
35. H.J. Møller, M. de Fost, H. Aerts, C. Hollak, and S.K. Moestrup Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease Eur J Haematol 72 2004 135 139
36. L.A. Boven, M. van Meurs, and R.G. Boot Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages Am J Clin Pathol 122 2004 359 369
37. E.M. Sherif, A.A. Tantawy, A.A. Adly, H.A. Kader, and E.A. Ismail D-dimer assay in Egyptian patients with Gaucher disease: correlation with bone and lung involvement Blood Coagul Fibrinolysis 22 3 2011 176 184
38. M. Jasiewicz, K. Kowal, O. Kowal-Bielecka, M. Knapp, R. Skiepko, and A. Bodzenta-Lukaszyk Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension Cytokine 66 2014 40 45
39. A.A. Tantawy, A.A. Adly, and E.A. Ismail Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications Blood Coagul Fibrinolysis 23 2012 640 648
40. L.A. Clarke, and C.E. Hollak The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders Best Pract Res Clin Endocrinol Metab 2014 [in press] (Available online 27 August 2014)
41. R.J. Wenstrup, M. Roca-Espiau, N.J. Weinreb, and B. Bembi Skeletal aspects of Gaucher disease: a review Br J Radiol 75 2002 A2 A12
42. D. Shitrit, B. Rudensky, A. Zimran, and D. Elstein D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement Am J Hematol 73 2003 236 239
43. Z. Sumarac, N. Suvajdžić, S. Ignjatović, N. Majkić-Singh, D. Janić, and M. Petakov Biomarkers in Serbian patients with Gaucher disease Clin Biochem 44 2011 950 954
44. R.G. Boot, M. Verhoek, M. de Fost, C.E. Hollak, M. Maas, and B. Bleijlevens Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention Blood 103 2004 33 39
45. A. Vellodi, B. Bembi, T.B. de Villemeur, T. Collin-Histed, A. Erikson, and E. Mengel Management of neuronopathic Gaucher disease: a European consensus J Inherit Metab Dis 24 2001 319 327
46. T.M. Cox, J.M. Aerts, G. Andria, M. Beck, N. Belmatoug, and B. Bembi Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N butyldeoxynojirimycin (miglustat) in the management of type I (nonneuronopathic) Gaucher disease: a position statement J Inherit Metab Dis 26 2003 513 526
47. A. Ashkenazi, R. Zaizov, and Y. Matoth Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease Eur J Pediatr 145 2003 138 141
48. S. Vom Dahl, L. Poll, M. Di Rocco, G. Ciana, C. Denes, and G. Mariani Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients Curr Med Res Opin 2 2006 10451064
49. C.E. Hollak, M. de Fost, L. van Dussen, S. Vom Dahl, and J.M. Aerts Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose-response relationships Expert Opin Pharmacother 10 2009 2641 2652
50. K.A. Hintz, A.J. Rassias, K. Wardwell, M.L. Moss, P.M. Morganelli, and P.A. Pioli Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163 J Leukoc Biol 72 2002 711 717
51. T.M. Cox Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses J Inherit Metab Dis 24 2001 106 121
52. H. Mizukami, Y. Mi, R. Wada, M. Kono, T. Yamashita, and Y. Liu Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage J Clin Invest 109 2002 1215 1221